PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

NEW YORK CITY -- An investigational 1-day aripiprazole initiation regimen was comparable in efficacy to usual treatment, according to a phase I study presented here. For the treatment of schizophrenia ...

Otsuka America Pharmaceutical Inc. and Lundbeck said the FDA has approved the expanded label of Abilify Maintena® (aripiprazole) for extended-release injectable suspension. The new deltoid injection ...

According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...

In addition, ABILIFY is available in a 1 mg/mL nonrefrigerated Oral Solution and as a single-dose, ready-to-use solution for intramuscular injection 7.5 mg/mL. In adult patients, the recommended ...

The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot. The Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a treatment for schizophrenia or bipolar I disorder. The injectable ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...

The first and only available dopamine partial agonist, ABILIFY is indicated for the short- and long-term treatment of schizophrenia including maintaining stability in adults who had been ...

The extended-release formulation of aripiprazole (Abilify Maintena, Otsuka Pharmaceutical Co, Ltd, and H. Lundbeck A/S) has been approved by the US Food and Drug Administration (FDA) for use as an ...